

Filed on behalf of Commonwealth Scientific and Industrial Research Organisation
by:

Gary J. Gershik
Cooper & Dunham LLP
30 Rockefeller Plaza
New York, NY 10112
(212)278-0400
ggershik@cooperdunham.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH
ORGANISATION,
Petitioner,

v.

BASF PLANT SCIENCE GMBH,
Patent Owner.

U.S. Patent No. 10,301,638

Issued: May 28, 2019

PETITION FOR POST-GRANT REVIEW

PURSUANT TO 35 U.S.C. §§ 321-328 AND C.F.R. § 42.200 *et seq.*

TABLE OF CONTENTS

I.	Introduction.....	1
II.	Mandatory Notices Under 37 C.F.R. § 42.8(A)(1).....	4
	A. Real Party-In-Interest Under 37 C.F.R. § 42.8(b)(1)	4
	1. Related parties	4
	B. Related Matters Under 37 C.F.R. § 42.8(b)(2).....	5
	1. Continuation applications.....	5
	2. Disputes between the parties.....	6
	C. Lead and Back Up Counsel Under 37 C.F.R. § 42.8(b)(3).....	7
	D. Service Information Under 37 C.F.R. § 42.8(b)(4).....	7
III.	Additional Requirements	7
	A. Payment of Fees Under 37 C.F.R. § 42.15.....	7
	B. Timing Under 37 C.F.R. § 42.202.....	7
	C. Grounds for Standing Under 37 C.F.R. § 42.204(a)	8
IV.	Technology Background.....	8
	A. Fatty acid nomenclature	8
	B. Fatty acid biosynthesis	11
	1. The aerobic biosynthetic pathway.....	12
	2. Transformation of plants with binary vectors	13
	C. Triacylglycerides and the fatty acid composition of plants	14
V.	Summary of the ‘638 Patent	15
	A. The disclosure of the ‘638 Patent and its priority applications.....	15
	1. The disclosure of the ‘638 Patent.....	15
	2. The disclosure of the priority applications.....	19
	B. The disclosure of the ‘638 Patent compared to the disclosure of Cirpus et al., PCT International Application Publication No. WO 2005/083093 A2, published September 9, 2005	20
	1. Binary vectors used for transformation of plant cells.....	22

2.	The ‘638 Patent recites in claims 18-23 the same codon-optimized $\Delta 5$ elongase that was disclosed in the earlier ‘093 publication	24
3.	Lipids produced by transformed plants.....	24
C.	Examination of the ‘638 Patent	25
1.	No statement of support was provided for the claims filed with the application	25
2.	There is no record of the Examiner analyzing the Written Description or Enablement of the claims during prosecution.....	26
3.	There is no record of the Examiner analyzing Enablement provided by the disclosure of the ‘638 Patent when accepting PO’s arguments that the disclosure of WO 2005/083093 did not enable certain claimed features.....	26
VI.	Statement of the Precise Relief Requested and the Reasons Therefor Under 37 C.F.R. § 42.22(A) and 37 C.F.R. § 42.204(b)	32
A.	Claim Construction (37 C.F.R. § 42.204(b)(3)).....	36
B.	Person of Ordinary Skill in the Art	38
VII.	The ‘638 Patent is PGR Eligible.....	38
A.	The ‘638 Patent should have been examined under the AIA.....	40
B.	The Priority Applications Lack Written Description Support	41
1.	Legal Standard for Written Description.....	41
2.	Ground 1: No Written Description for oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant comprising “at least 54% by weight of polyunsaturated $\omega 3$ -fatty acids” recited in claims 8-16	42
3.	Ground 2: No Written Description for “at least 20% by weight of EPA, at least 2% by weight of docosapentaenoic acid (DPA), and at least 4% by weight of docosahexaenoic acid (DHA) based on the total fatty acids in the transgenic [<i>Brassica</i>] plant in the form of triacylglycerides,” recited in 1-8, and 17-23.....	48
4.	Ground 3: No Written Description for “at least 20% by weight of EPA based on the total fatty acids in the transgenic [<i>Brassica</i>] plant in the form of triacylglycerides” recited in claim 11	54

5.	Ground 4: No Written Description for “at least 2% by weight of DPA based on the total fatty acids in the transgenic [<i>Brassica</i>] plant in the form of triacylglycerides” recited in claim 12	54
6.	Ground 5: No Written Description for “at least 4% by weight of DHA based on the total fatty acids in the transgenic [<i>Brassica</i>] plant in the form of triacylglycerides” recited in claim 13	54
7.	Ground 6: No Written Description for the amounts of EPA, DPA “and” DHA at “the sn-1, sn-2 or sn-3” position recited in claim 2	55
8.	Ground 7: No Written Description for the amounts of EPA, DPA “and” DHA at “the sn-2 position” recited in claim 3.....	57
9.	Ground 8: No Written Description for “at least 30% long chain polyunsaturated fatty acids (LCPUFAs) based on the total fatty acids in the transgenic [<i>Brassica</i>] plant” recited in claims 5 and 14	57
10.	Ground 9: No Written Description for “about 25% by weight of EPA in the form of triacylglycerides based on the total fatty acids in the transgenic [<i>Brassica</i>] plant” recited in claims 6 and 15	60
11.	Ground 10: No Written Description for “about 30% by weight of EPA and DHA in the form of triacylglycerides based on the total fatty acids in the transgenic [<i>Brassica</i>] plant” recited in claims 7 and 16.....	61
12.	Ground 11: No Written Description for the amounts of EPA, DPA, and DHA recited in claim 17 “based on the total fatty acids in the transgenic [<i>Brassica</i>] plant.”	61
C.	Lack of Enablement in the Priority Applications.....	61
1.	Legal Standard for Enablement.....	61
2.	Ground 12: Oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant comprising “at least 54% by weight of polyunsaturated ω 3-fatty acids,” recited in claims 8-16, are not enabled	64
3.	Ground 13: Oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant comprising “at least 20% by weight of EPA, at least 2% by weight of docosapentaenoic acid (DPA), and at least 4% by	

weight of docosahexaenoic acid (DHA) based on the total fatty acids in the transgenic [*Brassica*] plant in the form of triacylglycerides,” recited in claims 1-8 and 17-23 are not enabled67

4. Ground 14: Oils, lipids and/or fatty acids produced by a transgenic *Brassica* plant comprising “at least 20% by weight of EPA based on the total fatty acids in the transgenic [*Brassica*] plant in the form of triacylglycerides,” recited in claim 11 is not enabled.....72

5. Ground 15: Oils, lipids and/or fatty acids produced by a transgenic *Brassica* plant comprising “at least 2% by weight of DPA based on the total fatty acids in the transgenic [*Brassica*] plant in the form of triacylglycerides,” recited in claim 12 is not enabled72

6. Ground 16: Oils, lipids and/or fatty acids produced by a transgenic *Brassica* plant comprising “at least 4% by weight of DHA based on the total fatty acids in the transgenic [*Brassica*] plant in the form of triacylglycerides,” recited in claim 13 is not enabled72

7. Ground 17: The amounts of EPA, DPA and DHA at the sn-1, sn-2 or sn-3 positions recited in claim 2 are not enabled.....73

8. Ground 18: The amounts of EPA, DPA and DHA at the sn-2 position recited in claim 3 are not enabled74

9. Ground 19: Oils, lipids and/or fatty acids produced by a transgenic *Brassica* plant comprising “at least 30% long chain polyunsaturated fatty acids (LCPUFAs) based on the total fatty acids in the transgenic [*Brassica*] plant,” recited in claims 5 and 14, are not enabled75

10. Ground 20: Oils, lipids and/or fatty acids produced by a transgenic *Brassica* plant comprising “about 25% by weight of EPA based on the total fatty acids in the transgenic [*Brassica*] plant,” recited in claims 6 and 15, are not enabled77

11. Ground 21: Oils, lipids and/or fatty acids produced by a transgenic *Brassica* plant comprising “about 30% by weight of EPA and DHA in the form of triacylglycerides based on the total fatty acids in the transgenic [*Brassica*] plant,” recited in claims 7 and 16, are not enabled77

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.